Herbal and dietary supplements for treatment of anxiety disorders

American Family Physician

Volumn 76, Issue 4, 2007, Pages 549-556

  Saeed, Sy Atezaz ^a,b   Bloch, Richard M ^a   Antonacci, Diana J ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; BACOPA MONNIERI EXTRACT; CANNABIS; CHAMOMILE; CLOMIPRAMINE; CRATAEGUS EXTRACT; CYANOCOBALAMIN; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; GLYCYRRHIZA EXTRACT; HERBACEOUS AGENT; HYPERICUM EXTRACT; INOSITOL; KAVA EXTRACT; MELATONIN; NICOTINAMIDE; OMEGA 3 FATTY ACID; OXAZEPAM; PASSIFLORA INCARNATA EXTRACT; PHYTOESTROGEN; PLACEBO; PREGNENOLONE; PYRIDOXINE; SEROTONIN UPTAKE INHIBITOR; SYMPATHYL; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALERIAN; WITHANIA SOMNIFERA EXTRACT;

AGITATION; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIET SUPPLEMENTATION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; EOSINOPHILIA MYALGIA SYNDROME; HUMAN; LIVER TOXICITY; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN COLOR; SKIN DEFECT; SOCIAL PHOBIA; SOMATOFORM DISORDER; UNSPECIFIED SIDE EFFECT;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DIETARY SUPPLEMENTS; HUMANS; HYPERICUM; KAVA; PHYTOTHERAPY; PLANT PREPARATIONS; RANDOMIZED CONTROLLED TRIALS; SELF MEDICATION;

EID: 34548301907     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Eisenberg DM, Davis RB, Ettner Sl, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998;280:1569-75.
2. Unutzer J, Klap R, Sturm R, Young AS, Marmon T, Shatkin J, et al. Mental disorders and the use of alternative medicine: results from a national survey. Am J Psychiatry 2000;157:1851-7.
3. Kessler RC, Soukup J, Davis RB, Foster DF, Wilkey SA, Van Rompay MI, et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry 2001;158:289-94.
4. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev 2003;(1):CD003383.
5. Witte S, loew D, Gaus W. Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Phytother Res 2005;19:183-8.
6. Connor KM, Payne V, Davidson JR. Kava in generalized anxiety disorder: three placebo-controlled trials. Int Clin Psychopharmacol 2006;21:249-53.
7. Boerner RJ, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel M. Kava-kava extract lI 150 is as effective as opipramol and buspirone in generalised anxiety disorder - an 8-week randomized, double-blind multicentre clinical trial in 129 out-patients. Phytomedicine 2003;(10 suppl 4):38-49.
8. Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders - a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 1997;30:1-5.
9. Connor KM, Davidson JR, Churchill lE. Adverse-effect profile of kava. CNS Spectr 2001;6:848, 850-3.
10. Clouatre Dl. Kava kava: examining new reports of toxicity. Toxicol lett 2004;150:85-96.
11. Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration. Kava-containing dietary supplements may be associated with severe liver injury. Accessed March 20, 2007, at: http://www.cfsan.fda.gov/~dms/ addskava.html.
12. Simkins A, Thurston D, Colyar M, Talbot S. Nature's wrath? A closer look at complications with five popular herbs. Adv Nurse Pract 2005;13:55-6, 58.
13. Singh YN. Potential for interaction of kava and St. John's wort with drugs. J Ethnopharmacol 2005;100:108-13.
14. Singh YN, Singh NN. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs 2002;16:731-43.
15. Ernst E. The risk-benefit profile of commonly used herbal therapies: ginkgo, St. John's wort, ginseng, echinacea, saw palmetto, and kava [Published correction appears in Ann Intern Med 2003;138:79]. Ann Intern Med 2002;136:42-53.
16. Kobak KA, Taylor lV, Bystritsky A, Kohlenberg CJ, Greist JH, Tucker P, et al. St. John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int Clin Psychopharmacol 2005;20:299-304.
17. Taylor lH, Kobak KA. An open-label trial of St. John's wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 2000;61:575-8.
18. Kobak KA, Taylor lV, Warner G, Futterer R. St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study. J Clin Psychopharmacol 2005;25:51-8.
19. Volz HP, Murck H, Kasper S, Moller HJ. St. John's wort extract (lI 160) in somatoform disorders: results of a placebo-controlled trial [Published correction appears in Psychopharmacology (Berl) 2003;167:333]. Psychopharmacology (Berl) 2002;164:294-300.
20. Muller D, Pfeil T, von den Driesch V. Treating depression comorbid with anxiety - results of an open, practice-oriented study with St. John's wort WS 5572 and valerian extract in high doses. Phytomedicine 2003; (10 suppl 4):25-30.
21. Andreatini R, Sartori VA, Seabra Ml, leite JR. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 2002;16:650-4.
22. Hanus M, lafon J, Mathieu M. Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders. Curr Med Res Opin 2004;20:63-71.
23. Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther 2001;26:363-7.
24. Benjamin J, levine J, Fux M, Aviv A, levy D, Belmaker RH. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 1995;152:1084-6.
25. Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol 2001;21:335-9.
26. Fux M, levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996;153:1219-21.
27. Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a doubleblind cross-over study. Int J Neuropsychopharmacol 1999;2:193-5.
28. Schruers K, van Diest R, Overbeek T, Griez E. Acute l-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients. Psychiatry Res 2002;113:237-43.
29. Kahn RS, Westenberg HG, Verhoeven WM, Gispende Wied CC, Kamerbeek WD. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int Clin Psychopharmacol 1987;2:33-45.